National Cancer Institute.
Blood. 2012 Jul 12;120(2):238-40. doi: 10.1182/blood-2012-04-422501.
In this issue of Blood, Chesi et al show that their genetically engineered mouse model of multiple myeloma can predict positive or negative activity of drugs previously tested in clinical trials.
在本期《Blood》中,Chesi 等人表明,他们的多发性骨髓瘤基因工程小鼠模型可以预测之前在临床试验中测试过的药物的阳性或阴性活性。